DeFloria Announces Positive Results from Phase 1 Trial of AJA001 Being Developed for the Treatment of Autism Spectrum Disorder (ASD)

DeFloria Announces Positive Results from Phase 1 Trial of AJA001 Being Developed for the Treatment of Autism Spectrum Disorder (ASD)

/PRNewswire/ -- DeFloria, a joint venture between Ajna BioSciences and Charlotte's Web (TSX: CWEB, OTCQX: CWBHF), reported positive results from a Phase 1...

Charlotte's Web Provides Update on DeFloria's Phase 1 Results Targeting Autism Spectrum Disorder - PressReach

Promising Findings Presented at the American College of Neuropsychopharmacology Annual Meeting LOUISVILLE, Colo., Dec. 12, 2024  /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”) the market leader in cannabidiol (CBD) hemp extract wellness products, is pleased to share an update on the progress of DeFloria LLC’s (“DeFloria”) botanical pharmaceutical development, an entity established by…

Cannabis-based autism drug shines in phase-1 testing

DeFloria, a joint venture between Charlotte’s Web (TSX:CWEB), Ajna BioSciences and British American Tobacco, yielded positive results from a phase-1 dose trial of AJA001, its cannabis-based drug candidate to treat symptoms of autism spectrum disorder Results show that AJA001 was well-tolerated with a favorable pharmacokinetic profile Charlotte’s Web specializes in wellness products made from hemp extracts including CBD and CBN Charlotte’s Web st…

DeFloria advances cannabis-based autism drug through early trial

DeFloria announced Thursday that its experimental cannabis-based drug for autism spectrum disorder showed positive early results, with patients tolerating the treatment well across multiple dose levels. The drug, AJA001, being developed as a multi-compound hemp extract with a full spectrum of cannabinoids, demonstrated safety at daily doses up to 660 mg... Please login to read all 402 words.

DeFloria’s advances cannabis-based autism drug through early trial

DeFloria announced Thursday that its experimental cannabis-based drug for autism spectrum disorder showed positive early results, with patients tolerating the treatment well across multiple dose levels. The drug, AJA001, being developed as a multi-compound hemp extract with a full spectrum of cannabinoids, demonstrated safety at daily doses up to 660 mg... Please login to read all 402 words.